iData Insights

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 03, 2016 13:30 IST

This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179114/leishmaniasis-kala-azar-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179114/leishmaniasis-kala-azar-pipeline-review-h2-2015

Table of Contents

R&D Progress 82

Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small molecules to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Synthetic Peptides for Infectious Disease - Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

visceral leishmaniasis vaccine - Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

VL-2098 - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Leishmaniasis (Kala-Azar) - Recent Pipeline Updates 88

Leishmaniasis (Kala-Azar) - Dormant Projects 92

Leishmaniasis (Kala-Azar) - Discontinued Products 93

Leishmaniasis (Kala-Azar) - Product Development Milestones 94

Featured News & Press Releases 94

Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 94

Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 94

Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014 94

Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 95

Dec 17, 2012: PATHs Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh 96

Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 97

Appendix 98

Methodology 98

Coverage 98

Secondary Research 98

Primary Research 98

Expert Panel Validation 98

Contact Us 98

Disclaimer 99" width="80" height="40" />m of Action 82

R&D Progress 82

Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small molecules to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Synthetic Peptides for Infectious Disease - Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

visceral leishmaniasis vaccine - Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

VL-2098 - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Leishmaniasis (Kala-Azar) - Recent Pipeline Updates 88

Leishmaniasis (Kala-Azar) - Dormant Projects 92

Leishmaniasis (Kala-Azar) - Discontinued Products 93

Leishmaniasis (Kala-Azar) - Product Development Milestones 94

Featured News & Press Releases 94

Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 94

Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 94

Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014 94

Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 95

Dec 17, 2012: PATHs Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh 96

Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 97

Appendix 98

Methodology 98

Coverage 98

Secondary Research 98

Primary Research 98

Expert Panel Validation 98

Contact Us 98

Disclaimer 99

Read More http://www.idatainsights.com/reports-landing-page.php?id=179114/leishmaniasis-kala-azar-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.